Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our high-tech, dedicated method is applied to construct targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P62316
UPID:
SMD2_HUMAN
Alternative names:
snRNP core protein D2
Alternative UPACC:
P62316; A8K797; J3KPM5; P43330
Background:
Small nuclear ribonucleoprotein Sm D2, also known as snRNP core protein D2, is integral to pre-mRNA splicing, serving as a core component of the spliceosomal U1, U2, U4, and U5 small nuclear ribonucleoproteins (snRNPs). These snRNPs are the building blocks of the spliceosome, essential for the splicing of pre-mRNAs, including U12-type introns. The protein is a component of both the pre-catalytic spliceosome B complex and activated spliceosome C complexes, highlighting its multifaceted role in RNA processing.
Therapeutic significance:
Understanding the role of Small nuclear ribonucleoprotein Sm D2 could open doors to potential therapeutic strategies.